Stuart Therapeutics completes Phase 3 trial of vezocolmitide for treatment of dry eye disease
Topline data results are expected in February 2025.
Topline data results are expected in February 2025.
The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.
Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell,…
This Viewpoint examines results from the LIGHTSIDE trials for photobiomodulation to treat age-related macular degeneration and raises questions regarding the trial protocols and the efficacy…
Learn about Glaucoma, Glaucoma signs and symptoms, and how to prevent blindness from Gluacoma
While the overall global burden of avoidable visual impairment is projected to decline over the next 15 years, the number of cases is projected to…
This cohort study examines additional data for children from the Bifocal Lenses in Nearsighted Kids (BLINK) Study to determine whether axial eye growth increases after…
The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
KOLOA, Hawaii —When dealing with complications during surgery, have a plan in place to retain the patient’s trust, according to a panel discussion at Hawaiian…